Lv4
474 积分 2023-10-17 加入
Beyond suppression: the paradox of JAK inhibitors as amplifiers of cancer immunotherapy
13小时前
已完结
Enlonstobart: First Approval
2个月前
已完结
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial
3个月前
已完结
Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial
3个月前
已完结
An ambispective, real-world multi-center study of DOstarlimab in patients with Recurrent or Advanced DNA mismatch repair deficient/microsatellite instability-high endometrial cancer (GEICO 120-R/DORA study)
3个月前
已完结
Evaluation of the combination lenvatinib and pembrolizumab in endometrial cancer; a real world multi-institutional review of practice patterns, efficacy and tolerability
3个月前
已完结
An ambispective, real-world multi-center study of DOstarlimab in patients with Recurrent or Advanced DNA mismatch repair deficient/microsatellite instability-high endometrial cancer (GEICO 120-R/DORA study)
3个月前
已完结
The role of neoadjuvant chemotherapy in clinically advanced endometrial cancer: a real-world retrospective single-institutional study
3个月前
已关闭
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial
3个月前
已完结
How I treat advanced phases of CML
3个月前
已完结
皖公网安备34019202002308
